Introduction and Objective: Dyslipidemia is common among renal transplant recipients and may be a risk factor for cardiovascular disease and graft dysfunction. The present study investigated the prevalence of dyslipidemia and predictors for the onset of dyslipidemia within 1 year after transplantation among patients on tacrolimus (TAC) and mycophenolate mofetil (MMF).
Methods. One hundred twenty six renal allograft recipients (78 males and 48 females) who underwent transplantation under TAC and MMF based-immunosuppression between February 2002 and August 2011 were analyzed. Patients who had low-density lipoprotein cholesterol levels above 140 mg/dl, triglyceride levels above 150 mg/dl, and high-density lipoprotein cholesterol levels below 40 mg/dl in the first year after transplantation, or those who required an oral statin were diagnosed as having dyslipidemia. In addition, the association between dyslipidemia, 60 genomic polymorphisms, and long-term allograft survival were assessed.
Results. Within 1 year after transplantation, 44 recipients (34.9%) were diagnosed with dyslipidemia. No significant differences were observed for mean age, mean body mass index, acute rejection rate, diabetes mellitus, or hyperuricemia between the patients with dyslipidemia and those without. The frequency of hypertension was higher in patients with dyslipidemia (p=0.030). The body weight-adjusted daily dose of prednisolone (PSL) and MMF at 28 days after transplantation was related to dyslipidemia (p=0.023 and p=0.012, respectively). The prevalence of dyslipidemia was significantly higher in patients with the glucocorticoid receptor Bcl I G allele than in those with the CC genotype (p= 0.008). A multivariate analysis revealed that the glucocorticoid receptor Bcl I G allele was independently associated with dyslipidemia (odds ratio=10.7, 95% confidence interval 1.7-11.5, P=0.030). Graft survival rates of patients with and without dyslipidemia did not differ significantly.
Conclusion. The prevalence of dyslipidemia in our cohort was 34.9%. The glucocorticoid receptor Bcl I G allele may influence the occurrence of dyslipidemia. This finding may aid in predicting a patients risk of the developing dyslipidemia.
To cite this abstract in AMA style:Numakura K, Satoh S, Saito M, Komine N, Akihama S, Inoue T, Narita S, Tsuchiya N, Habuchi T. Dyslipidemia in the First Year after Renal Transplantation: Its Prevalence, Associated Clinical and Genomic Factors, and Graft Survival [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/dyslipidemia-in-the-first-year-after-renal-transplantation-its-prevalence-associated-clinical-and-genomic-factors-and-graft-survival/. Accessed July 7, 2020.
« Back to 2013 American Transplant Congress